Extraordinarily high serum CA 19-9 in setting of pancreatic necrosis and underlying pancreatic adenocarcinoma: a case report

被引:0
|
作者
McConnell, Ashlyn [1 ]
Stoneman, Tyler [2 ]
Hewlett, Stanley [1 ]
机构
[1] Princeton Baptist Med Ctr, Dept Surg, Birmingham, AL 35211 USA
[2] Edward Via Coll Osteopath Med, Spartanburg, SC 29303 USA
来源
JOURNAL OF SURGICAL CASE REPORTS | 2023年 / 2023卷 / 10期
关键词
pancreatic cancer; CA; 19-9; jaundice; tumor markers;
D O I
10.1093/jscr/rjad550
中图分类号
R61 [外科手术学];
学科分类号
摘要
Carbohydrate antigen (CA 19-9) is the most validated marker for both sensitivity and specificity of pancreatic adenocarcinoma used to aid diagnosis of symptomatic patients as well as to evaluate the progression or treatment of disease. Though higher levels of CA 19-9 tend to correlate with neoplastic disease, elevated levels are also often seen in patients with benign gastrointestinal diseases, such as obstructive jaundice and pancreatitis. We present a case of a 74-year-old male who was admitted for abdominal pain and worsening jaundice who was diagnosed with extensive pancreatic necrosis and an underlying invasive pancreatic adenocarcinoma whose serum level of CA 19-9 was found to be extraordinarily high.
引用
收藏
页数:2
相关论文
共 50 条
  • [21] CA 19-9 and pancreatic carcinoma, a revival?
    Ducreux, Michel
    Boige, Valerie
    Malka, David
    ONKOLOGIE, 2007, 30 (1-2): : 12 - 13
  • [22] Thrombin Generation is Associated With CA 19-9 In Vitro and in Pancreatic Ductal Adenocarcinoma
    Mattila, N.
    Przybyla, B.
    Seppanen, H.
    Haglund, C.
    Lassila, R.
    PANCREAS, 2018, 47 (10) : 1409 - 1409
  • [23] Utility of CA 19-9 in Predicting Metastatic Pancreatic Adenocarcinoma in Veteran Patients
    Ramzan, Zeeshan
    Kim, David
    Nassri, Ammar
    Zhu, Hong
    Mokdad, Ali
    Huerta, Sergio
    Kukreja, Sachin
    Polanco, Patricio
    Spechler, Stuart
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S9 - S9
  • [24] Ca 19-9 Response to Neoadjuvant Therapy Predicts Outcome in Pancreatic Adenocarcinoma
    Boone, B. A.
    Steve, J.
    Zenati, M. S.
    Hogg, M. E.
    Zureikat, A. H.
    Zeh, H. J.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S159 - S159
  • [25] Traumatic abdominal pain and normal CA 19-9 concealing pancreatic adenocarcinoma
    Lee, A
    Inverso, N
    Komar, M
    Rusynyk, A
    Grundfast, M
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (09): : S186 - S186
  • [26] The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates
    Poruk, K. E.
    Gay, D. Z.
    Brown, K.
    Mulvihill, J. D.
    Boucher, K. M.
    Scaife, C. L.
    Firpo, M. A.
    Mulvihill, S. J.
    CURRENT MOLECULAR MEDICINE, 2013, 13 (03) : 340 - 351
  • [27] Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons
    Goh, Su Kah
    Gold, Grace
    Christophi, Christopher
    Muralidharan, Vijayaragavan
    ANZ JOURNAL OF SURGERY, 2017, 87 (12) : 987 - 992
  • [28] The value of serum carbohydrate antigen 19-9 as a predictor of resectability in pancreatic adenocarcinoma
    Albatanony, Ayman A.
    Alseesi, Alaa A.
    EGYPTIAN JOURNAL OF SURGERY, 2015, 34 (04): : 226 - 229
  • [29] Serum levels of CA 19-9 in patients with pancreatic cancer and liver cirrhosis
    Kadayifci, A
    Simsek, H
    Usalan, C
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1995, 14 (04) : 435 - 437
  • [30] Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review
    Ballehaninna U.K.
    Chamberlain R.S.
    Indian Journal of Surgical Oncology, 2011, 2 (2) : 88 - 100